Shareholders just greenlit a major move. The business combination between Sonnet BioTherapeutics and Hyperliquid Strategies Inc. got the official stamp of approval through voting.

This merger signals a strategic shift for both entities. Hyperliquid's expansion into new operational territory could reshape how the ecosystem positions itself in the competitive landscape. The vote marks a critical milestone—shareholders betting on synergy over standalone growth.

Bob Diamond mode activated. When institutional players start consolidating, markets pay attention. The Hyperliquid name keeps surfacing in strategic conversations, and this corporate maneuver adds another layer to its evolving narrative.